Seqens

  • % held
    0 %
    % managed
    0 %
    2018 revenue
    0 M€
    picto
  • Investment date
    June 2016
    picto
    Governance
    6 / 9
    picto
    in a 9 members board of directors
Dernière mise à jour : 18 / 04 / 2019
  • % held
    0 %
    % managed
    0 %
    2018 revenue
    0 M€
    picto
  • Investment date
    June 2016
    picto
    Governance
    6 / 9
    picto
    in a 9 members board of directors
Dernière mise à jour : 18 / 04 / 2019
  • % held
    0 %
  • % managed
    0 %
  • 2018 revenue
    0 M€
    picto
  • Investment date
    June 2016
    picto
  • Governance
    6 / 9
    picto
    in a 9 members board of directors
Dernière mise à jour : 18 / 04 / 2019

- ABOUT -

A global player in pharmaceutical synthesis and specialty chemicals, Seqens produces and distributes essential products used in everyday life, today and for the future, such as aspirin, paracetamol, other APIs, salicylic acid, para-aminophenol, soda ash, sodium bicarbonate, phenol, oxygenated solvents and ferric chloride.

With strong positions in the growing and resilient pharmaceutical & healthcare, cosmetics & fragrances and food & feed markets, Seqens offers a wide range of products and services.

The group has a solid European platform complemented by a well-established presence in Asia and an increasing footprint in North America. Headquartered in Lyon (France), the group employs over 3,000 people across 35 industrial facilities worldwide and has more than 1,000 customers in over 80 countries.

Learn more

- INVESTMENT CASE -

What was the transformation objective?

The common goal is to accelerate the group’s growth by bolstering its position in its five target markets, which combine both resilience and high growth, and by continuing to develop additional products for its current portfolio, particularly high added-value specialty products such as APIs, sodium bicarbonate or oxygenated solvents.

To achieve this, Seqens will draw on its ability to innovate and an external growth policy based on partnerships and targeted acquisitions, mainly in the pharmaceutical and cosmetics industries. This will also help to boost its international coverage, both industrially and commercially.

How will Eurazeo assist Seqens with this transformation?

Eurazeo provides its international networks (particularly in the United States and China) and the necessary human and financial resources to create a proactive external growth policy. Seqens can also rely on the Eurazeo teams to pursue the roll-out of an ambitious CSR strategy for example

- CSR Initiative example -

In 2017, Seqens carried out a carbon audit on Novacarb and Novabion in order to assess the importance of Scope 3 emissions in the site’s overall footprint. It is planned to extend the approach to other Novacap sites, as it is a key step in the process of identifying potential gains and determining action plans to reduce emissions.

At the One Planet Summit, the group signed the French Business Climate Pledge, a commitment by French companies to the climate. The signatory companies affirm the need to collectively change course in order to achieve a drastic reduction in Greenhouse Gas (GHG) emissions globally.

Languages